Skip to main content

Day: June 8, 2020

Mesa Air Group Reports May 2020 Operating Performance

PHOENIX, June 08, 2020 (GLOBE NEWSWIRE) — Mesa Air Group, Inc. (NASDAQ: MESA) today reported Mesa Airlines’ operating performance for May 2020.Mesa Airlines reported 12,077 block hours in May 2020, a 68.6 percent drop from May 2019 as a result of reduced schedules during the COVID-19 outbreak. The company also reported a controllable completion factor of 100 percent for both its American and United operations.Operating statistics for April 2020 and fiscal year 2020 YTD are included in the table below.*Controllable Completion Factor excludes cancellations due to weather and air traffic control**Total Completion Factor includes all cancellationsAbout Mesa Air Group, Inc.Headquartered in Phoenix, Arizona, Mesa Air Group, Inc. is the holding company of Mesa Airlines, a regional air carrier providing scheduled passenger service to 99...

Continue reading

Summit Appoints Michael Donaldson as Chief Financial Officer

Summit Therapeutics plc (‘Summit’ or the ‘Company’)Summit Appoints Michael Donaldson as Chief Financial OfficerOxford, UK, and Cambridge, MA, US, June 8, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today announces that Mr. Michael Donaldson has been appointed as Chief Financial Officer, effective immediately. Mr. Donaldson brings to Summit over 20 years of finance experience, including the last nine years working in corporate finance.“Michael joins us at an exciting time in Summit’s growth with our ongoing Phase 3 clinical trials of our precision antibiotic candidate, ridinilazole, and the potential to bring a superior product to patients with C. difficile infection,” said Mr. Bob Duggan, Executive Chairman and Chief Executive Officer of Summit. “We welcome Michael’s expertise across a range of financial solutions for biotech companies...

Continue reading

ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 08, 2020 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced a virtual presentation of data from the Company’s Phase 1/2 trial of sepofarsen. The data will be shared via a video presentation through the Association for Research in Vision and Ophthalmology (ARVO). It is the first time this data, previously announced in a press release and conference call in October 2019, will be presented in association with an ophthalmology medical congress.Due to COVID-19, the ARVO 2020 Annual Meeting was cancelled and instead video-recorded presentations will be available on ARVOLearn, ARVO’s online learning platform.Details of ProQR’s presentation are...

Continue reading

Genco Shipping & Trading Leads the First Full Crew Change Under New COVID-19 Protocols in Singapore

NEW YORK, June 08, 2020 (GLOBE NEWSWIRE) — Genco Shipping & Trading Limited (NYSE:GNK) (“Genco” or the “Company”), the largest U.S. headquartered drybulk shipowner focused on the transportation of major and minor bulk commodities globally, announced the successful full crew change of the Genco Liberty, a 180,032 DWT Capesize vessel, marking the first full crew change under new COVID-19 protocols in Singapore.  A total of 37 seafarers were involved in this crew change, which was completed on June 6, 2020 and executed in accordance with protocols established by Genco, Singapore’s Maritime and Port Authority (MPA) and the Synergy Group.John C. Wobensmith, Chief Executive Officer, commented, “Amid the outbreak of COVID-19, many individuals have been onboard oceangoing vessels in excess of the duration of their contracts, keeping...

Continue reading

Non-Small Cell Lung Cancer Therapeutics Market to reach US$ 43,713.1 Mn, Growing Adoption of Targeted Therapy for Diagnosis to Boost the Market, says Fortune Business Insights

Pune, June 08, 2020 (GLOBE NEWSWIRE) — The global non-small cell lung cancer therapeutics market is growing impressively due to recent surge in adoption of targeted therapy for treating non-small cell lung cancer. According to a report published by Fortune Business Insights, titled ‘Non-Small Cell Lung Cancer Therapeutics: Global Market Analysis, Insights and Forecasts, 2019-2026,’ the market value will rise substantially from US$ 16,011.7 Mn in 2018 to US$ 43,713.1 Mn by 2026.Fortune Business Insights has further predicted the market to exhibit an impressive CAGR of 13.4% between 2019 and 2026 due to exceptional advancements in targeted therapy in recent years. Such high growth can be attributable to the increasing demand for chemotherapy and targeted therapy. Furthermore, advantages of targeted therapy over other alternatives...

Continue reading

Monterey Minerals Announces Exploration Plans at Alicia Project in the Philippines

TORONTO, June 08, 2020 (GLOBE NEWSWIRE) — Monterey Minerals Inc. (the “Company” or “Monterey”) (CSE:MREY and FSE:2DK) is pleased to announce its 2020 exploration plans on the Alicia high-grade gold and base metals project in Alicia Municipality, Philippines (“Alicia Project”).  The exploration focus for the 2020 exploration plan will be to prove continuity between the previously identified veins and better understand the bigger system at depth that the Company’s technical team believes is feeding these near-surface veins along the greater than eleven (11) kilometers of strike.  2020 Exploration Plan Highlights:Exploration drilling along strike down to a depth of 300 metres to:Discover the source of the veins at surface and test the geologist’s premise that the vein systems are merging at depthDefine the down-dip continuity/extension...

Continue reading

CENTOGENE to Report First-Quarter 2020 Financial Results on June 15, 2020

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 08, 2020 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that it will issue a press release reporting its financial results for the three months ended March 31, 2020 on Monday, June 15, 2020, and will host a conference call to discuss these results at 8 a.m. EST that day.Participants may access the conference call on June 15, 2020 by dialing U.S. toll free +1 877 870 9135 or U.K. +44 (0) 800 279 6619 up to 10 minutes prior to the start of the call and by providing the conference ID number 4799325. The webcast of the conference call can and the related earnings presentation...

Continue reading

DPW Holdings, Inc. Announces Adjournment of Special Meeting of Stockholders

NEWPORT BEACH, Calif., June 08, 2020 (GLOBE NEWSWIRE) — DPW Holdings, Inc. (NYSE American: DPW) a diversified holding company (“DPW,” or the “Company”) today announced the adjournment of the Company’s 2020 Special Meeting of Stockholders (the “Meeting”), which was scheduled to be held at 9:00 a.m. on June 8, 2020 but was postponed because due to the absence of quorum to conduct business.Based on the absence of quorum, the board of directors (the “Board”) elected to adjourn the Meeting until 9:00 a.m. (Pacific Time) on July 8, 2020 for the purpose of allowing additional time for stockholders to vote on the Proposals contained in the Proxy Statement dated May 18, 2020 (the “Proxy Statement”).As described in the Proxy Statement, the Meeting will be held for the following purposes:To approve the issuance of shares of the Corporation’s...

Continue reading

Providence Announces Strategic Conversion Agreement with Holder of Majority of Series A Convertible Preferred Stock

ATLANTA, June 08, 2020 (GLOBE NEWSWIRE) — The Providence Service Corporation (“Providence” or the “Company”) (Nasdaq: PRSC), the nation’s largest provider of non-emergency medical transportation (“NEMT”) programs and holder of a minority interest in Matrix Medical Network, today announced that the Company has entered into a strategic Conversion Agreement with Coliseum Capital Management, LLC (“Coliseum”), providing initially for the conversion of 738,240 shares of the Company’s 5.5%/8.5% Series A convertible preferred stock held by Coliseum into cash totaling approximately $80.7 million plus approximately 925,600 shares of Providence common stock. Coliseum owns approximately 96.5% of the Company’s preferred stock, or 765,916 preferred shares.After the initial conversion of Coliseum’s preferred shares, which is expected to occur...

Continue reading

Eldorado Gold to Begin Construction of the Decline at Lamaque and Provides an Update on Greece

VANCOUVER, British Columbia, June 08, 2020 (GLOBE NEWSWIRE) — Eldorado Gold Corporation (“Eldorado” or “the Company”) announces that it is commencing construction of a three kilometre decline, or tunnel (shown in Figures 1 and 2 below), from the Sigma mill to the 405 metre level of the Triangle mine. The Company is also providing an update on several positive developments in Greece.“We are pleased to begin construction of the decline at Lamaque this summer. This is a project that we have been advancing for nearly a year and is another step towards further production growth and continued value creation at Lamaque. We would like to thank the government of Quebec and all our local stakeholders for their continued support for this project and our Lamaque operations,” said George Burns President and CEO.Lamaque Decline ProjectThe fully...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.